Pfizer R&D In China: Building A Virtual R&D Network
This article was originally published in PharmAsia News
Executive Summary
While many multinational companies have taken a brick-and-mortar approach to R&D in emerging markets, Pfizer is betting that a virtual research network will give it the flexibility and access to talent it needs to succeed in China. Pfizer's president of global R&D, Martin Mackay, and Stephen Yang, who heads Pfizer's Asia R&D efforts, outline that strategy in a two-part interview. Two of the most important figures in Pfizer's worldwide research endeavors, Mackay and Yang were interviewed by Elsevier writers Ellen Licking and Wendy Diller. This is part one of the interview; part two will appear in an upcoming issue of PharmAsia News.
You may also be interested in...
Pfizer Returns To Japan To Identify Technology And Compound Targets
TOKYO - Two years after closing a research lab in Japan, Pfizer is looking to rebuild a focus on Japanese innovation and technology
Pfizer Returns To Japan To Identify Technology And Compound Targets
TOKYO - Two years after closing a research lab in Japan, Pfizer is looking to rebuild a focus on Japanese innovation and technology
Pfizer Signs Academic Collaboration Pact With Peking University To Support Translational R&D Center In Shenzhen
SHANGHAI - After unveiling a plan to build a research and development center in Wuhan last week, Pfizer announced it inked an agreement with Peking University Dec. 1 to fund the university's research projects and to build a translational research and drug discovery center in PKU's Graduate School in Shenzhen, a Chinese city that borders the former British enclave of Hong Kong